Phathom Pharmaceuticals, Inc. PHAT Stock-Based Comp
Stock-Based Comp at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Phathom Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: Phathom Pharmaceuticals, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Phathom Pharmaceuticals, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Phathom Pharmaceuticals, Inc.'s stock-based comp?
- Phathom Pharmaceuticals, Inc. (PHAT) reported stock-based comp of $5.53M in Q1 2026.
- How has Phathom Pharmaceuticals, Inc.'s stock-based comp changed year-over-year?
- Phathom Pharmaceuticals, Inc.'s stock-based comp decreased by 0.1% year-over-year, from $5.54M to $5.53M.
- What is the long-term trend for Phathom Pharmaceuticals, Inc.'s stock-based comp?
- Over 4 years (2021 to 2025), Phathom Pharmaceuticals, Inc.'s stock-based comp has grown at a 14.3% compound annual growth rate (CAGR), from $16.81M to $28.72M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.